Table 4.
Lesion size comparison table (Days 0–21)
| Day | Group | Outcome | P-value |
|---|---|---|---|
| Day 0 | All Groups | No significant differences in baseline lesion size; indicates randomization and homogeneity. | P > 0.05 |
| Day 14 | Group 1 (Glucantime®) | Greater lesion size reduction vs. Group 5 and Group 7. ⁽¹⁾ | P = 0.01 vs. G5; P = 0.0008 vs. G7 |
| Day 14 | Group 2 (SinaAmpholeish®) | Significant lesion reduction vs. control. | P = 0.0211 vs. G7 |
| Day 14 | Group 2 vs. Group 3 | No significant difference observed; similar therapeutic outcomes. |
NS )P = 0.480( |
| Day 21 | Group 1 (Glucantime®) | Most effective; significant difference vs. G2, G5, G7. ⁽²⁾ | P = 0.0246 vs. G2; ***P < 0.0001 vs. G5 & G7 |
| Day 21 | Group 3 (AmB-loaded Nanofiber) | Significant reduction vs. control group. | P = 0.0081 vs. G7 |
| Day 21 | Group 3 vs. Group 2 | No significant difference detected. |
NS )P = 0.769( |
| Day 21 | Group 5 & Group 7 | Progressive lesion enlargement observed. | — |
⁽¹⁾ Reflects the statistically superior response of Glucantime® vs. blank nanofiber and untreated groups at Day 14
⁽²⁾ Glucantime®’s high efficacy persisted to Day 21 with stronger statistical significance vs. all comparator groups